CoChat

Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance

Open access
Jain, Akshay B., Ali, Amar, Gorgojo Martínez, Juan J., Hramiak, Irene, Kavia, Ketan, Madsbad, Sten, Potier, Louis, Prohaska, Ben D., Strong, Jodi L., Vilsbøll, Tina · 2021 · International Journal of Clinical Practice
Cited by 44

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are an established treatment for patients with type 2 diabetes (T2D). Differences between GLP-1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) outcomes, mean there may be benefits to switching from one to another. However, clinical guidance on switching is lacking and data from clinical trials are limited. This article provides a clinical perspective and consensus on the benefits of switching between GLP-1RAs, the triggers for switching and how best to manage this in clinical practice. Once weekly (OW) semaglutide is used as an example to illustrate how the authors might switch to a different GLP-1RA in clinical practice. METHODS: Literature was searched and perspectives from 10 healthcare professionals with experience in switching patients with T2D to OW semaglutide from another GLP-1RA were collated. RESULTS: targets not being met, a desire for additional weight loss, poor adherence, patients moving to increased CV risk status and adverse effects with the current GLP-1RA. Non-medical triggers for switching included patient preference, cost, formulary changes and insurance mandates. Once the decision to switch is made, an individualised approach is recommended, based on considerations that include reimbursement requirements, treatment duration with (and dose of) previous GLP-1RA, the patient's experience initiating the prior GLP-1RA, any concomitant treatment and clinical characteristics. When switching, it is important to emphasise that treatment burden will not increase and that if gastrointestinal adverse effects occur, they are typically transient. Any transient gastrointestinal adverse effects that may occur (or recur) when switching to another GLP-1RA can be reduced by slow up-titration and advising patients to reduce food portion sizes and fat intake. CONCLUSION: Switching from one GLP-1RA to another, such as OW semaglutide, can provide clinical benefits and may delay the need for treatment intensification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ijcp.13731

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 44

Metadata

Authors
Jain, A. B., Ali, A., Gorgojo Martínez, J. J., Hramiak, I., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T.
Venue
International Journal of Clinical Practice
Publisher
Wiley
Published
2020-11-03
Volume
75
Issue
2
Pages
e13731-e13731
ISSN
  • 1368-5031 (ISSN-L)
  • 1742-1241
OpenAlex
W3088988988
Cited by
44
References
22
FWCI
3.18
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance. https://app.cochat.ai/papers/10.1111/ijcp.13731
The paper
Jain, A. B., Ali, A., Gorgojo Martínez, J. J., Hramiak, I., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T. (2021). Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance. International Journal of Clinical Practice. https://doi.org/10.1111/ijcp.13731

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.